Suppr超能文献

谷胱甘肽 S-转移酶 M1 多态性与中国腹膜透析患者临床结局的关系。

Relationship between glutathione S-transferase M1 polymorphism and clinical outcomes in Chinese peritoneal dialysis patients.

机构信息

Department of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong, China.

出版信息

J Nephrol. 2012 May-Jun;25(3):310-6. doi: 10.5301/jn.5000021.

Abstract

BACKGROUND

Oxidative stress contributes to cardiovascular diseases in peritoneal dialysis (PD) patients. Glutathione S-transferase M1 is an antioxidative enzyme encoded by the GST M1 gene. The GST M1 (-) genotype causes deficiency of the enzyme when compared with the GST M1 (+) genotype. We investigated the effects of the GST M1 (-)/(+) polymorphism on the clinical outcomes of Chinese PD patients.

METHODS

We studied 441 new PD patients (232 men, age 56.6 ± 13.5 years). GST M1 (-)/(+) polymorphism was determined by multiplex polymerase chain reaction. The patients were followed for 41.4 ± 18.2 months.

RESULTS

The GST M1 polymorphism was not associated with 5-year patient and technique survival in the whole cohort. However, there were significant interactions between age group and the GST M1 polymorphism on 5-year patient survival (p=0.046) and technique survival (p=0.049). Post hoc analysis showed that for patients =70 years old, those with the GST M1 (+) genotype had significantly better 5-year patient survival (62.5% vs. 26.2%; log rank test, p=0.012) and technique survival (55.1% vs. 21.9%; log rank test, p=0.024) than the GST M1 (-) group. For patients younger than 70 years, the GST M1 polymorphism did not affect 5-year patient or technique survival.

CONCLUSION

The GST M1 (+) genotype is associated with better survival in elderly PD patients, who may have heavy oxidative stress as a result of the aging and PD processes.

摘要

背景

氧化应激是腹膜透析(PD)患者心血管疾病的病因之一。谷胱甘肽 S-转移酶 M1(GST M1)是一种抗氧化酶,由 GST M1 基因编码。与 GST M1(+)基因型相比,GST M1(-)基因型会导致该酶的缺乏。我们研究了 GST M1(-)/(+)多态性对中国 PD 患者临床结局的影响。

方法

我们研究了 441 例新开始 PD 治疗的患者(232 名男性,年龄 56.6±13.5 岁)。采用多重聚合酶链反应检测 GST M1(-)/(+)多态性。对患者进行了 41.4±18.2 个月的随访。

结果

GST M1 多态性与整个队列的 5 年患者和技术生存率无关。然而,在年龄组与 GST M1 多态性之间存在 5 年患者生存率(p=0.046)和技术生存率(p=0.049)的显著交互作用。事后分析显示,对于年龄≥70 岁的患者,GST M1(+)基因型的患者 5 年生存率(62.5%比 26.2%;log rank 检验,p=0.012)和技术生存率(55.1%比 21.9%;log rank 检验,p=0.024)显著高于 GST M1(-)组。对于年龄<70 岁的患者,GST M1 多态性不影响 5 年患者或技术生存率。

结论

GST M1(+)基因型与老年 PD 患者的生存更好相关,这可能是由于衰老和 PD 过程导致的氧化应激增加所致。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验